ArticleNature communications2017
The anthelmintic praziquantel is a human serotoninergic G-protein-coupled receptor ligand.
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 71 citations in OpenAlex.
- Plant-Derived Terpenes as Emerging Therapeutics Against Schistosomiasis.International journal of molecular sciences · 2026Review
- Use of a cytochrome P450 humanized mouse model to refine schistosomiasis drug discovery.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Polypharmacology of anthelmintics at host and parasite ion channels.PLoS pathogens · 2026Article
- Structure-Activity Relationship and Target Investigation of Thiophen-2-yl-Pyrimidines againstbioRxiv : the preprint server for biology · 2025Article
- Escherichia coli is implicated in the development and manifestation of host susceptibility to the roundworm Trichostrongylus colubriformis infections in sheep.Veterinary research · 2025Article
- Progress interrogating TRPMPZQ as the target of praziquantel.PLoS neglected tropical diseases · 2024Review
- Perspective on Schistosomiasis Drug Discovery: Highlights from a Schistosomiasis Drug Discovery Workshop at Wellcome Collection, London, September 2022.ACS infectious diseases · 2023Review
- In vitro cestocidal activity ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2023Article
- Molecular and cellular basis of praziquantel action in the cardiovascular system.American journal of physiology. Cell physiology · 2023Article
- CaMKII regulates neuromuscular activity and survival of the human blood fluke Schistosoma mansoni.Scientific reports · 2022Article
- The interplay of helminthic neuropeptides and proteases in parasite survival and host immunomodulation.Biochemical Society transactions · 2022Review
- High-content approaches to anthelmintic drug screening.Trends in parasitology · 2021Review
- Single-cell deconstruction of stem-cell-driven schistosome development.Trends in parasitology · 2021Review
- Schistosoma mansoni alter transcription of immunomodulatory gene products following in vivo praziquantel exposure.PLoS neglected tropical diseases · 2021Article
- Characterization of a new type of neuronal 5-HT G- protein coupled receptor in the cestode nervous system.PloS one · 2021Article
- An up-to-date overview of computational polypharmacology in modern drug discovery.Expert opinion on drug discovery · 2020Review
- Activation of transient receptor potential channel Sm.(Schistosoma mansoni)TRPMParasitology research · 2020Review
- Schistosome TRP channels: An appraisal.International journal for parasitology. Drugs and drug resistance · 2020Review
- Heat shock protein 70 (Hsp70) inParasitology · 2020Review
- Current and Novel Therapies Against Helminthic Infections: The Potential of Antioxidants Combined with Drugs.Biomolecules · 2020Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 5 institutions in 2 countries.
Funding
Abstract
Schistosomiasis is a debilitating tropical disease caused by infection with parasitic blood flukes. Approximately 260 million people are infected worldwide, underscoring the clinical and socioeconomic impact of this chronic infection. Schistosomiasis is treated with the drug praziquantel (PZQ), which has proved the therapeutic mainstay for over three decades of clinical use. However, the molecular target(s) of PZQ remain undefined. Here we identify a molecular target for the antischistosomal eutomer - (R)-PZQ - which functions as a partial agonist of the human serotoninergic 5HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.